Hu Yue, Li Yuhao, Luo Yumin, Wang Ningqun, Zheng Yangmin
Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
Beijing Geriatric Medical Research Center, Beijing, China.
Transl Stroke Res. 2024 Nov 22. doi: 10.1007/s12975-024-01307-z.
Stroke, the leading cause of disability and the second leading cause of death worldwide, is characterized by high morbidity and disability. The lectin-like oxidized low-density lipoprotein receptor (LOX-1) is a scavenger receptor that promotes endothelial dysfunction by recognizing and internalizing oxidized low-density lipoproteins (ox-LDL) to induce the formation, development, and instability of atherosclerotic plaques, ultimately leading to vascular thrombosis. Previous clinical and epidemiological studies have indicated that LOX-1 plays a vital role in cerebral ischemic injury following ischemic stroke. Multiple clinical studies have shown that the genetic polymorphisms in LOX-1 are associated with susceptibility to ischemic stroke. Soluble LOX-1 (sLOX-1), a biomarker of ischemic stroke, is associated with the prognosis of ischemic stroke. This article discusses the clinical and experimental findings on LOX-1 in ischemic stroke and the development of new therapeutic strategies targeting LOX-1.
中风是全球致残的主要原因和第二大死因，其特点是高发病率和高致残率。凝集素样氧化低密度脂蛋白受体（LOX-1）是一种清道夫受体，它通过识别和内化氧化低密度脂蛋白（ox-LDL）来促进内皮功能障碍，从而诱导动脉粥样硬化斑块的形成、发展和不稳定，最终导致血管血栓形成。先前的临床和流行病学研究表明，LOX-1在缺血性中风后的脑缺血损伤中起着至关重要的作用。多项临床研究表明，LOX-1的基因多态性与缺血性中风的易感性有关。可溶性LOX-1（sLOX-1）作为缺血性中风的生物标志物，与缺血性中风的预后相关。本文讨论了缺血性中风中LOX-1的临床和实验研究结果以及针对LOX-1的新治疗策略的进展。
